IGF1 and osteosarcoma: A precision oncology approach using the combination of dasatinib with ceritinib, an insulin like growth factor (IGF) pathway inhibitor in a patient with osteosarcoma after demonstrating benefit of the combination in vitro in the patient derived cell line, showed the combination was safe, but the effect was short lived (Beck et al., 2020).